Farnesyltransferase Inhibitors in Cancer Therapy
With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer...
| Other Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Totowa, NJ
Humana
2001, 2001
|
| Edition: | 1st ed. 2001 |
| Series: | Cancer Drug Discovery and Development
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- 1 Signal Transduction Pathways: A Goldmine for Therapeutic Targets
- 2 The Biochemistry of Farnesyltransferase and Geranylgeranyltransferase I
- 3 Structures of Protein Farnesyltransferase
- 4 Peptidomimetic-Based Inhibitors of Farnesyltransferase
- 5 Antitumor Efficacy of a Farnesyltransferase Inhibitor in Transgenic Mice
- 6 Development of Farnesyltransferase Inhibitors as Potential Antitumor Agents
- 7 Tricyclic Farnesyl Protein Transferase Inhibitors: Antitumor Activity and Effects on Protein Prenylation
- 8 Histidylbenzylglycinamides: A Novel Class of Farnesyl DiphosphateCompetitive Peptidic Farnesyltransferase Inhibitors
- 9 From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase
- 10 Genetic Analysis of FTase and GGTase I and Natural Product Farnesyltransferase Inhibitors
- 11 Effects of Farnesyltransferase Inhibitors on Cytoskeleton, Cell Transformation, and Tumorigenesis: The FTI-Rho Hypothesis
- 12 Prenyltransferase Inhibitors as Radiosensitizers
- 13 Farnesyltransferase and Geranylgeranyltransferase I Inhibitors as Novel Agents for Cancer and Cardiovascular Diseases
- 14 Protein Prenylation in Trypanosomatids: A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases
- 15 Early Clinical Experience with Farnesyl Protein Transferase Inhibitors: From the Bench to the Bedside
- 16 Phase I Trial of Oral R115777 in Patients with Refractory Solid Tumors: Preliminary Results
- 17 Farnesyltransferase and Geranylgeranyltransferase Inhibitors: The Saga Continues